(688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase II Clinical Study of the Subsidiary's SGC001 Innovative Drug for Indication of "Predicted Severe Acute Pancreatitis"
· Issued by Beijing Hotgen Biotech Co. Ltd. via Shanghai Stock Exchange
Filed with SSE · Stock code 688068 · · 2 pages · Chinese
Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase II Clinical Study of the Subsidiary's SGC001 Innovative Drug for Indication of "Predicted Severe Acute Pancreatitis"
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
